A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 6, 2022

Primary Completion Date

November 8, 2022

Study Completion Date

November 8, 2022

Conditions

Hepatic Impairment

Interventions

DRUG

Cedirogant

Capsule, Oral

Trial Locations (3)

Orlando Clinical Research Ctr /ID# 246052, Orlando

Clinical Pharmacology of Miami /ID# 246573, Miami

TX Liver Inst, Americ Res Corp /ID# 246572, San Antonio